background
part
india
chandipura
viru
chpv
emerg
enceph
caus
pathogen
epidem
sporad
form
pediatr
diseas
follow
rapid
cours
lead
mortal
absenc
specif
treatment
effect
rna
interfer
rnai
evalu
method
find
efficaci
synthet
short
interf
rna
sirna
short
hairpin
rna
shrna
protect
mice
chpv
infect
assess
target
gene
p
gene
primarili
import
role
former
viral
replic
lethal
natur
latter
real
time
one
step
rtpcr
plaqu
assay
use
assess
gene
silenc
use
show
sirna
effici
reduc
express
p
gene
invitro
quantit
assay
document
reduct
viru
titer
sirna
transfect
post
infect
pi
use
sirna
combin
result
enhanc
effici
sirna
found
toler
four
mismatch
center
compar
five
differ
shrna
sirna
effect
inhibit
chpv
replic
extend
surviv
note
mice
infect
intracrani
ld
chpv
treat
cation
lipid
complex
mg
sirna
simultan
infect
treatment
two
dose
sirna
first
simultan
second
hr
pi
result
surviv
surviv
mice
show
less
chpv
titer
brain
without
histopatholog
chang
antibodi
respons
gene
express
profil
sirna
treat
mice
show
interferon
respons
first
dose
sirna
pi
second
dose
result
surviv
respect
suggest
potenti
applic
therapi
result
highlight
therapeut
potenti
sirna
treat
rapid
fatal
chandipura
enceph
chandipura
viru
chpv
emerg
encephalitiscaus
pathogen
india
belong
famili
rhabdovirida
genu
vesiculoviru
outbreak
chpv
report
state
andhra
pradesh
gujarat
maharashtra
nation
institut
virolog
niv
unpublish
data
mortal
vari
children
endem
area
sporad
diseas
also
record
chpv
neg
sens
rna
genom
approxim
kb
encod
differ
protein
nucleocapsid
n
protein
phosphoprotein
p
protein
matrix
protein
glycoprotein
g
protein
larg
l
protein
p
protein
import
function
viru
life
cycl
transcript
replic
rna
interfer
rnai
posttranscript
process
trigger
introduct
doublestrand
rna
dsrna
subsequ
cleav
dicer
nt
small
interf
rna
sirna
sirna
unwound
risc
rna
induc
silenc
complex
presenc
atp
activ
risc
bind
degrad
target
mrna
guid
singl
strand
sirna
recent
year
rnai
emerg
power
tool
gene
silenc
potenti
therapeut
use
viral
infect
human
immunodefici
viru
hiv
influenza
respiratori
syncyti
viru
rsv
sar
coronaviru
ebola
viru
sever
studi
shown
central
nervou
system
cn
also
acquiesc
rnai
case
brain
cancer
spinocerebellar
ataxia
intracrani
inject
sirna
shown
immens
potenti
suppress
enceph
caus
two
flavivirus
jev
japanes
enceph
viru
wnv
west
nile
viru
control
nonseg
negativestrand
rna
viru
replic
cultur
cell
sirna
well
document
recent
studi
shown
inhibit
rabi
viru
replic
multipl
artifici
microrna
amirna
neuro
cell
consid
recent
emerg
rapidli
progress
viral
infect
lead
enceph
high
fatal
proport
children
india
absenc
specif
treatment
rnai
base
intervent
explor
suppress
chpv
infect
mice
human
embryon
kidney
hek
cell
use
sirna
studi
vero
cell
use
plaqu
assay
chandipura
viru
isol
andhra
pradesh
epidem
use
throughout
studi
clone
express
p
gene
chpv
p
gene
chpv
amplifi
revers
transcriptas
polymeras
chain
reaction
rtpcr
use
primer
without
stop
codon
clone
vector
name
cell
transfect
mg
transfect
cell
observ
floresc
microscop
period
check
express
green
fluoresc
protein
gfp
fuse
chpv
p
protein
confirm
western
blot
use
antigfp
antibodi
invitrogen
carlsbad
ca
usa
chpv
sequenc
present
genbank
sequenc
new
isol
gener
lab
niv
unpublish
data
use
design
sirna
sirna
design
use
hp
onguard
sirna
design
tabl
fig
four
sirna
synthes
p
gene
gene
respect
target
cdna
strand
neg
control
sirna
ncsirna
signific
homolog
known
mammalian
gene
use
nonsilenc
control
rnai
experi
purchas
qiagen
catalog
number
neg
control
plasmid
ncp
use
shrna
experi
ambion
usa
http
hpguaranteedaspx
transfect
sirna
amaxa
nucleofactor
ii
devic
supplement
kit
v
solut
use
suggest
manufactur
transfect
use
hiperfect
reagent
cell
seed
hr
transfect
sixwel
plate
per
well
lipidsirna
complex
prepar
incub
pmol
sirna
hiperfect
reagent
qiagen
valencia
ca
appropri
volum
recommend
manufactur
determin
transfect
effici
sirna
tag
alexa
use
qiagen
valencia
ca
p
gene
sirna
valid
cell
transfect
p
gene
sirna
concentr
pmol
mg
target
express
plasmid
hr
post
transfect
cell
harvest
flow
cytometri
real
time
one
step
rtpcr
carri
real
time
one
step
rtpcr
rna
isol
use
rnaeasi
minikit
qiagen
valencia
ca
describ
figur
schemat
represent
gene
arrang
chpv
sirna
use
p
gene
target
sirna
synthesi
number
assign
arbitrarili
indic
locat
refer
tabl
correct
locat
sirna
differ
sirna
use
determin
toler
mismatch
use
sirna
number
parenthes
repres
posit
mismatch
incorpor
sequenc
sirna
mutant
refer
cell
infect
plaqu
form
unit
pfu
chpv
cell
transfect
pmol
differ
sirna
hr
pi
cell
supernat
harvest
hr
post
transfect
rna
isol
use
qiamp
viral
rna
minikit
qiagen
valencia
ca
real
time
one
step
rtpcr
carri
describ
earlier
determin
effect
combin
sirna
replic
chpv
concentr
pmol
sirna
use
alon
differ
combin
real
time
one
step
rtpcr
flowcytometri
plaqu
assay
assess
gene
silenc
total
rna
cell
transfect
mous
brain
sampl
viral
rna
supernat
chpv
infect
cell
subject
real
time
one
step
rtpcr
describ
earlier
flowcytometri
acquisit
done
use
facscalibur
bd
bioscienc
analys
perform
use
cell
quest
softwar
bd
bioscienc
plaqu
assay
vero
cell
grown
near
confluenc
tissu
cultur
plate
cell
adsorb
serial
dilut
supernat
contain
chpv
min
follow
adsorpt
cell
wash
pb
fed
ml
mem
sigma
usa
along
wv
carboxymethyl
cellulos
sigma
usa
cell
incub
day
observ
plaqu
invert
microscop
stain
crystal
violet
fix
vv
formal
salin
plaqu
count
titer
viru
calcul
pfuml
investig
toler
rnai
system
mismatch
sirna
rel
target
mrna
differ
sirna
mismatch
specif
posit
shown
tabl
comparison
sirna
short
hairpin
rna
shrna
effici
deliv
sirna
shrna
format
compar
effici
sirna
shrna
sequenc
sirna
subject
link
wwwambioncomtechlibmisc
psilencerconverterhtml
dna
oligo
synthes
name
depend
upon
plasmid
promot
use
express
shrna
follow
report
document
hypersuscept
mice
vsv
infect
result
impair
express
examin
contribut
replic
chpv
use
bioinformat
tool
http
cbcsrv
rnahybrid
http
bibiservtechfakunibielefelddernahybridsubmissionhtml
reveal
chpv
p
gene
two
potenti
bind
site
confirm
role
chpv
replic
assess
use
stem
loop
differ
combin
use
psilenc
neo
vector
ambion
appli
biosystem
intern
foster
citi
ca
name
precursor
sequenc
stem
replac
sirna
stem
loop
replac
sirna
respect
use
oligo
synthes
idt
usa
tabl
sens
antisens
oligo
anneal
ligat
either
psilenc
neo
psilenc
cmv
neo
vector
ambion
appli
biosystem
intern
foster
citi
ca
recommend
manufactur
clone
screen
restrict
digest
confirm
sequenc
endofre
maxi
prep
made
quantit
differ
shrna
express
plasmid
mg
cotransfect
individu
plasmid
ng
hr
post
transfect
cell
harvest
rna
isol
real
time
one
step
rtpcr
fac
analysi
carri
differ
shrna
express
plasmid
individu
transfect
hr
post
transfect
cell
infect
pfuml
chpv
hr
post
pi
supernat
assay
presenc
chpv
plaqu
assay
real
time
one
step
rtpcr
balbc
mice
age
wk
use
vivo
experi
experi
done
biosafeti
level
anim
facil
niv
approv
institut
anim
ethic
committe
iaec
anim
experiment
mice
inocul
intracrani
ic
chpv
experi
use
sirna
sirna
complex
hiperfect
tm
qiagen
valencia
ca
accord
manufactur
instruct
administ
site
simultan
differ
interv
mous
tissu
prepar
real
time
one
step
rtpcr
gene
express
histopatholog
mice
n
euthan
brainsspleen
remov
use
variou
experi
histopatholog
brain
sampl
fix
neutral
buffer
formalin
embed
paraffin
vertic
section
stain
hematoxylin
eosin
quantit
assess
chpv
replic
mice
brain
use
real
time
one
step
rtpcr
rna
isol
use
ribopur
rna
isol
kit
ambion
usa
accord
manufactur
instruct
ng
total
rna
use
per
reaction
gene
express
analysi
use
taqman
low
densiti
array
tlda
singlecel
suspens
spleen
prepar
gentli
tabl
mutant
sirna
use
determin
toler
mismatch
sirna
target
sequenc
chang
shown
bold
teas
rpmi
medium
rna
isol
rna
spleen
mice
n
group
pool
sampl
run
duplic
fast
real
time
pcr
machin
appli
biosystem
intern
foster
citi
ca
data
analysi
done
use
rq
softwar
respect
control
uninfecteduntr
hprt
use
endogen
control
statist
analys
done
use
xlstat
program
excel
softwar
three
independ
experi
perform
triplic
result
express
mean
sd
data
analyz
one
way
anova
follow
dunnett
test
vivo
experi
mice
surviv
compar
use
logrank
mental
cox
gehanbreslowwilcoxon
test
graphpad
prism
softwar
evalu
version
initi
rapid
effici
assess
gene
silenc
p
gene
chpv
express
gfp
fusion
protein
fluoresc
microscopi
western
blot
confirm
express
p
protein
fuse
gfp
molecular
weight
fusion
protein
approxim
kda
molecular
weight
gfp
protein
kda
molecular
weight
bacteri
express
p
protein
kda
confoc
microscopi
cell
transfect
show
cytoplasm
local
fusion
protein
p
gene
sirna
valid
chpv
hr
post
transfect
cell
transfect
p
gene
sirna
target
express
plasmid
show
sirna
could
reduc
gfp
express
p
gene
express
approxim
fig
c
c
wherea
effect
respect
chpv
efficaci
sirna
reduc
replic
hr
evidenc
plaqu
assay
real
time
one
step
rtpcr
fig
dose
respons
experi
use
pmol
sirna
show
pmol
optimum
concentr
fig
gene
sirna
test
viru
effici
compar
sirna
result
show
equal
potent
inhibit
chpv
induc
cytopath
effect
observ
phasecontrast
microscopi
magnif
fig
assess
viru
replic
plaqu
assay
real
time
one
step
rtpcr
show
inhibit
chpv
thu
confirm
efficaci
three
sirna
fig
initi
tri
combin
sirna
differ
concentr
sirna
pfuml
cell
could
infect
inhibit
observ
concentr
sirna
pmol
tabl
sequenc
shrna
oligo
use
optimum
reduct
achiev
figur
depict
effici
sirna
use
alon
differ
combin
sirna
case
reduct
viral
titer
compar
control
record
infect
chpv
low
pfuml
high
pfuml
alter
effici
sirna
reduct
case
fig
toler
mismatch
sirna
could
toler
mismatch
singl
nucleotid
posit
two
adjac
mutat
four
consecut
posit
judg
chpv
result
show
least
p
gene
silenc
fig
differ
titter
chpv
mutant
sirna
treat
control
cell
fig
short
hairpin
rna
shrna
valid
plasmid
chpv
flowcytometeri
real
time
one
step
rtpcr
document
shrna
express
either
pol
iii
pol
ii
promot
effici
sirna
valid
done
reduct
approxim
fig
silenc
effect
last
till
fig
lost
test
chpv
differ
treat
control
cell
sirna
use
posit
control
show
activ
similar
experi
conduct
earlier
transfect
effici
alexa
sirna
either
nucleofact
hiperfect
reagent
cell
respect
measur
flowcytometri
cell
infect
pfuml
chpv
treat
sirna
hiperfect
less
effect
nucleofact
reduct
less
invivo
experi
hiperfect
reagent
use
deliveri
sirna
adult
mice
suscept
chpv
peripher
rout
intracrani
rout
use
infect
viru
first
experi
chpv
use
simultan
treatment
either
sirna
mg
ncsirna
mg
complex
hiperfect
site
led
surviv
day
former
day
latter
group
fig
anoth
experi
viru
dose
reduc
ld
mice
receiv
one
simultan
two
dose
ug
sirna
first
group
anim
show
extend
surviv
hr
mice
follow
surviv
one
mous
importantli
surviv
record
mice
receiv
two
dose
sirna
fig
accord
extend
surviv
viral
titr
brain
tissu
mice
treat
two
dose
sirna
reduc
compar
control
group
fig
histopatholog
brain
ncsirna
treat
mice
show
typic
featur
viral
enceph
mening
vessel
perivascular
cuf
lymphocyt
fig
focu
gliosi
demyelin
cortex
fig
absenc
brain
inflamm
neuropatholog
obviou
sirnatr
mice
fig
mice
group
sacrif
th
day
postchpv
inocul
order
rule
induct
nonspecif
interferon
respons
sirna
tlda
perform
gene
express
chang
fold
consid
signific
express
ifn
fig
express
chemokin
gene
surfac
receptor
molecul
fasl
fold
upregul
initi
phase
infect
decreas
later
time
point
fig
c
none
chang
observ
chpv
infect
mice
record
mice
treat
sirna
control
mice
receiv
sirna
complex
hiperfect
data
clearli
show
protect
offer
sirna
specif
reflect
nonspecif
antivir
respons
ifn
antichpigg
antibodi
absent
day
postinfect
sirna
treat
surviv
mice
consid
therapeut
import
abil
sirna
clear
establish
chpv
infect
also
evalu
two
dose
sirna
mg
apart
found
give
protect
respect
treatment
given
postinfect
fig
b
follow
recognit
emerg
chpv
emerg
pathogen
caus
rapid
high
mortal
children
india
nation
institut
consid
restrict
spread
viru
undertook
two
approach
probabl
strategi
combat
infect
develop
prophylact
vaccin
sirna
administr
probabl
therapeut
agent
present
studi
abl
identifi
potent
sirna
could
protect
mice
lethal
enceph
even
viru
directli
introduc
target
organ
brain
first
step
select
viral
gene
target
rnai
select
p
gene
p
protein
indispens
activ
l
protein
function
rna
depend
rna
polymeras
rdrp
protein
lethal
protein
encod
rhabdovirus
account
induct
cytopath
effect
apoptosi
cell
initi
total
sirna
p
gene
gene
screen
invitro
cotransfect
plasmid
p
gene
sirna
identifi
sirna
potent
perturb
p
gene
express
fig
gene
sirna
directli
valid
viru
sirna
equal
effici
inhibit
chpv
induc
cytopath
effect
fig
replic
inhibit
sirna
treat
cell
also
confirm
reduct
viru
titer
evidenc
plaqu
assay
real
time
one
step
rtpcr
fig
unfortun
use
combin
effect
sirna
differ
concentr
yield
addit
benefit
possibl
explan
could
cell
limit
capac
assembl
rnainduc
silenc
complex
risc
sirna
compet
avail
risc
pool
present
cell
similar
observ
report
two
respiratori
virus
respiratori
syncyti
viru
parainfluenza
viru
assess
specif
inhibit
chpv
replic
sirna
treat
cell
assess
g
gene
p
genebas
real
time
pcr
respect
data
shown
case
reduct
record
may
reflect
possibl
sirna
target
cognat
mrna
also
posit
strand
pregenom
rna
thu
affect
overal
replic
viru
far
p
gene
full
genom
chpv
isol
sequenc
unpublish
data
percent
nucleotid
ident
pni
p
gene
vari
thu
viru
chang
appreci
period
year
despit
stabl
natur
viru
toler
mismatch
sirna
examin
molecul
evalu
invivo
experi
though
mismatch
center
sirna
duplex
critic
abolish
target
cleavag
introduct
differ
mismatch
show
inhibit
viru
reduc
rate
fig
thu
even
viru
mutat
sirna
still
effect
consid
sever
advantag
offer
shrna
requir
low
dose
longterm
downregul
target
gene
econom
altern
sirna
also
tri
shrna
format
though
effici
silenc
observ
efficaci
lost
fig
could
possibl
apoptosi
subsequ
inhibit
host
transcript
induc
protein
chpv
vsv
infect
similar
find
abrog
dna
base
rnai
found
apoptot
cell
due
mediat
inactiv
without
affect
risc
depend
part
rnai
therefor
sirna
seem
better
approach
regul
chpv
replic
especi
acut
infect
rapid
cours
longterm
treatment
need
howev
recent
studi
efficaci
shrna
effect
shown
treatment
jev
enceph
mice
use
lentivir
vector
surviv
record
mice
inject
ic
pseudotyp
rvg
lentivir
vector
express
shrna
specif
jev
challeng
half
hour
later
ld
jev
site
encourag
invitro
result
attempt
evalu
sirna
murin
model
avail
select
suitabl
deliveri
system
key
question
although
success
use
nake
sirna
target
painrel
cation
channel
treat
chronic
neuropath
pain
rat
model
report
poor
uptak
brain
parenchym
cell
shown
studi
recent
cation
lipid
formul
ifect
neurom
found
deliv
sirna
neuron
cell
without
toxic
could
protect
mice
viral
enceph
caus
flavivirus
use
sirna
complex
cation
lipid
hiperfect
deliveri
brain
simultan
administr
mg
sirna
viru
result
hr
delay
respect
appear
symptom
death
fig
b
one
mous
surviv
lower
dose
viru
importantli
two
dose
mg
sirna
administ
hr
apart
mice
surviv
experi
first
dose
sirna
given
simultan
viru
examin
degre
protect
offer
sirna
administ
viru
inocul
differ
two
dose
schedul
tri
ie
hr
inocul
fig
surviv
reduc
respect
consid
rapid
chpv
replic
result
signific
could
introduc
larg
amount
sirna
postinfect
surviv
mice
seem
like
due
limit
volum
could
tri
pertin
note
je
viru
singl
inject
contain
sirna
jetsidop
led
complet
protect
need
tri
differ
liposom
formul
encapsul
optimum
concentr
sirna
achiev
near
surviv
administ
infect
viru
variabl
interv
sirna
dose
yield
optimum
protect
dose
apart
addit
paramet
evalu
daili
monitor
chpv
titer
brain
real
time
one
step
rtpcr
fig
clearli
show
reduct
mice
treat
sirna
compar
ncsirna
treat
control
histopatholog
analysi
demonstr
sirna
treat
mice
brain
exhibit
common
featur
viral
enceph
seen
exclus
control
group
fig
order
prove
figur
histopatholog
mice
brain
treat
sirna
hematoxylin
eosinstain
vertic
brain
section
control
mice
treat
ncsirna
infect
chpv
b
sirna
treat
mice
th
day
pi
c
indic
magnif
protect
offer
inde
due
sirna
screen
sera
surviv
mice
day
infect
presenc
antichpigg
antibodi
absenc
antibodi
demonstr
limit
viral
replic
lead
develop
humor
respons
data
shown
gener
addit
inform
immun
respons
gene
express
profil
studi
use
spleen
brain
primarili
aim
dissect
effect
chpv
infect
regul
gene
mice
limit
compar
express
level
immun
respons
gene
among
sirna
treat
control
mice
receiv
dose
viru
regard
paper
koterski
et
al
venazuelan
equin
enceph
viru
veev
noteworthi
ifn
shown
antivir
effect
vsv
chpv
evidenc
invitro
human
studi
respect
fig
clearli
document
excess
upregul
ifn
gene
earli
stage
infect
pi
follow
drastic
decreas
thu
though
ifn
produc
larg
quantiti
combat
infect
desir
effect
achiev
lead
death
importantli
elev
record
virusinfect
sirna
treat
well
control
mice
receiv
vehicl
alon
involv
suppress
protect
immun
respons
elev
initi
phase
time
death
cytokin
might
play
crucial
role
pathogenesi
chpv
elev
express
tnf
found
decreas
time
consist
previou
report
document
suscept
tnfa
knockout
ko
mice
lethal
enceph
suppressor
cytokin
signal
gene
play
critic
role
neg
regul
cytokin
signal
steadili
decreas
initi
elev
result
similar
studi
rabi
viru
infect
wherein
downregul
gene
shown
elev
level
suggest
recruit
activ
dendrit
cell
macrophag
neutrophil
white
cell
site
infect
howev
tnf
ifnc
known
induc
deceas
level
tnf
ifnc
correl
well
downregul
studi
fasl
upregul
begin
infect
deceas
fasl
known
induc
apoptosi
brain
cell
viral
enceph
gene
profil
result
clearli
demonstr
none
gene
modul
cours
chpv
infect
affect
sirna
treat
mice
confirm
sirna
allow
replic
chpv
real
time
histopatholog
also
score
brain
neg
chpv
therefor
lead
cascad
immun
reaction
lead
either
recoveri
death
absenc
antichp
antibodi
provid
similar
evid
nutshel
report
identif
effici
sirna
potent
protect
mice
lethal
enceph
induc
chpv
util
cation
lipid
effect
brain
deliveri
preliminari
import
find
taken
logic
conclus
conduct
addit
studi
mention
earlier
includ
trial
rhesu
monkey
